| Literature DB >> 22732552 |
Xiu-Qing Yao1, Xia-Chun Li, Xiao-Xue Zhang, Yang-Yang Yin, Bin Liu, Dan-Ju Luo, Qun Wang, Jian-Zhi Wang, Gong-Ping Liu.
Abstract
Protein phosphatase-2A (PP2A) activity is significantly suppressed in Alzheimer's disease. We have reported that glycogen synthase kinase-3β (GSK-3β) inhibits PP2A via upregulating the phosphorylation of PP2A catalytic subunit (PP2A(C)). Here we studied the effects of GSK-3β on the inhibitory demethylation of PP2A at leucine-309 (dmL309-PP2A(C)). We found that GSK-3β regulates dmL309-PP2A(C) level by regulating PME-1 and PPMT1. Knockdown of PME-1 or PPMT1 eliminated the effects of GSK-3β on PP2A(C). GSK-3 could negatively regulate PP2A regulatory subunit protein level. We conclude that GSK-3β can inhibit PP2A by increasing the inhibitory L309-demethylation involving upregulation of PME-1 and inhibition of PPMT1.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22732552 DOI: 10.1016/j.febslet.2012.06.018
Source DB: PubMed Journal: FEBS Lett ISSN: 0014-5793 Impact factor: 4.124